Axura USA

Roman name

Akatinol Memantine

Pharmacokinetics

Once inside quickly and completely absorbed. C_max in plasma achieved through 2-6 hours Netting place in two phases. T_1/2 averages in the first phase, 4-9 p, the second with 40-65 hours Report mostly kidneys (90%). With normal kidney function cumulation reported.

Indications

Degeneratius dementia (alzgeimerovsky type), vascular dementia, mixed dementia of all degrees of severity. Reducing memory, the ability to concentrate in learning ability. Stroke and spinalny spasticeski syndrome, as a result of head trauma, MS, stroke.

Pregnancy and lactation

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity expressed by the human kidney, pregnancy, breast-feeding.

Specific guidance

Patients older preferably appoint product in the form of drops.

Patient interaction

Axura Memantine aggravating barbiturates, Neuroleptics, antiholinergicakih funds. You can change the effect dantrolena and baklofena.

Overdosing

Perhaps increased side effects.

Precautions

Be wary appointed to epilepsy, in patients тиреотоксикозом.Опти��альная The dose is gradually weekly increase.

Storage conditions

B. List in a dry place so that the temperature does not exceed 25 ° C

Shelf life

3 years

The registration

014961/01-2003

Directory → Neurotropic funds → Other means of neurotropic → Axura USA